RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Motsch J., de Oliveira C. M., Stus V., Koksal I., Lyulko O., Boucher H. W., ...Daha Fazla

CLINICAL INFECTIOUS DISEASES, cilt.70, sa.9, ss.1799-1808, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 70 Sayı: 9
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1093/cid/ciz530
  • Dergi Adı: CLINICAL INFECTIOUS DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Environment Index, Food Science & Technology Abstracts, International Pharmaceutical Abstracts, MEDLINE, Public Affairs Index, Veterinary Science Database
  • Sayfa Sayıları: ss.1799-1808
  • Anahtar Kelimeler: carbapenem resistant, KPC, nosocomial pneumonia, cIAI, cUTI, DISEASES SOCIETY, CLINICAL-PRACTICE, GUIDELINES, ASSOCIATION, RELEBACTAM, MANAGEMENT, MEROPENEM, AMERICA, PHASE-2, ADULTS
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background: The beta-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections.